India, Jan. 27 -- Dr Harith Rajagopalan looks at the booming market for weight-loss drugs like Wegovy and Ozempic and sees a multi-billion dollar bonfire. While millions have flocked to GLP-1 agonists to treat obesity and diabetes, studies show a sobering reality: most patients stop taking the injections within two years, erasing long-term cardiovascular benefits and wasting billions in healthcare spending. Also read | Endocrinologist explains dark side of weight loss drugs: Potential risks and benefits of Ozempic, Mounjaro, Wegovy

Dr Rajagopalan, a cardiologist and co-founder of the biotech firm Fractyl Health, believes the solution isn't a better needle, but a fundamental rewrite of human biology. His company is preparing for human cli...